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Introduction
Parasitic helminths pose significant health problems for humans and also their domestic animals and livestock. This knowledge has resulted in widespread attempts to design vaccines and although these have been largely unsuccessful a great deal has been learned about the immunological relationship between helminth and host (reviewed in Maizels et al. (1999) , Moreau and Chauvin (2010) ). It is now clear that parasitic helminths have evolved a number of strategies for interfering with or modulating the immune system of the parasitized host (reviewed in Maizels and Yazdanbakhsh (2003) ). Furthermore, a number of individual helminth products with immunomodulatory properties have now been defined (reviewed in Harnett and Harnett (2010) ). A pattern, which is emerging is that these products are often anti-inflammatory and hence they have been studied in mouse models of diseases that are associated with inflammation in the search for novel anti-inflammatory drugs. This policy is consistent with the currently popular idea that parasitic worm infections may protect humans against the development of autoimmune and allergic diseases (reviewed in Helmby (2009) ).
The possibility that defined helminth products could ultimately see use in the clinic argues for an understanding of their effects on the immune system at the molecular level. It would be prudent to establish for example, the identity of the receptors that they interact with and the effects that receptor ligation have on downstream signaling pathways. Certainly such information is beginning to emerge with respect to several defined helminth immunomodulators (reviewed in Everts et al. (2010) , Harnett and Harnett (2010) , Perrigoue et al. (2008) , van Die and Cummings (2009) ). One of these helminth molecules is ES-62, a secreted product of the rodent filarial nematode Acanthocheilonema viteae that is amongst the best characterized of the helminth-derived immunomodulators. It is a phosphorylcholine (PC)-containing molecule whose anti-inflammatory properties allow it to provide significant protection against the development of arthritis and allergy in mouse models and the PC moiety appears to be largely responsible for immunomodulatory activity (reviewed in Harnett and Harnett (2009) ). Studies investigating the effects of ES-62 on antigen-presenting cells (APC) -macrophages and dendritic cells showed, via the use of knockout mice, that ES-62-induced immunomodulatory effects on these cells was dependent on the presence of MyD88 and TLR4 but not TLR2 (Goodridge et al., 2005) . The reliance on TLR4 appeared atypical in that unlike bacterial LPS, ES-62 was found to be active against APC obtained from C3H/HeJ mice, which have a point mutation in TLR4. PC conjugated to ovalbumin 0014-4894/$ -see front matter Ó 2011 Elsevier Inc. All rights reserved. doi:10.1016/j.exppara.2011.09.001 (OVA) can mimic ES-62's effects on APC and this is also dependent on both MyD88 and TLR4 and like ES-62, PC-OVA is also effective in C3H/HeJ mice (Goodridge et al., 2007) .
Although ES-62 activity in APC has been shown to be dependent on TLR4, this is not the only potential cell surface receptor for it. Thus, ES-62, possibly via its high mannose glycan moiety (Haslam et al., 1997) , has been found to bind a soluble form of the mannose receptor and we also have some evidence suggesting that, perhaps as befits a PC-containing molecule, it is able to interact with cells via the PAF receptor (unpublished results). Although we have yet to put biological significance to these additional interactions ( (Goodridge et al., 2007) and unpublished results) they clearly indicate the possibility of multiple receptor usage by ES-62. Furthermore, it is possible that different cells of the immune system may bind ES-62 via distinct receptors or alternatively, differential TLR4-containing receptor complexes. In relation to this, in this manuscript we examine receptor usage by ES-62 on lymphocytes and myeloid cells and we present evidence to suggest that the receptors that ES-62 uses varies amongst cell types.
Materials and methods

ES-62, mice and cells
Purified ES-62 from A. viteae was prepared as described previously (Goodridge et al., 2005) . Wild type BALB/c and C57BL/6 mice were obtained from Harlan Olac (Bicester, UK). TLR4
À/À and MyD88 À/À mice (C57BL/6 background) were a generous gift from Prof. S. Akira, University of Osaka, Osaka, Japan to Dr. K. Else and Dr. S. Tötemeyer at the Universities of Manchester and Cambridge, UK, respectively. Mice and gerbils (used in production of ES-62) are housed and employed in experiments as indicated under home office licenses obtained from the UK government. Bone marrow-derived macrophages (bmMs) were prepared as described previously (Goodridge et al., 2004) . Murine B cells (>98% sIg + ) were prepared using the CD43-magnetic bead negative-selection method of Miltenyi Biotec as described previously (Deehan et al., 2001 ). U937 cells, WEHI-231 B cells and Jurkat T cells were cultured as described previously (Harnett et al., 1998; Katz et al., 2004; Smith et al., 2003) .
Biacore analysis
Analysis was carried out using CM5 research-grade biosensor chips in a biacore biosensor BIAcore 2000 (Uppsala, Sweden) as described previously (Mistrik et al., 2004) . Briefly, ES-62 was immobilized on channels of CM5 chips using an amine coupling procedure and various membrane preparations screened for binding as indicated by an increase in the surface plasmon resonance (SRP) signal due to the alteration in refractive index caused by binding of a biomolecule(s) to the chip, followed by analysis of the dissociation phase. The fourth channel of the chip was left uncoated and used as the control reference cell to allow subtraction of background/non-specific binding of the membrane preparations to the chips. The kinetics parameters were derived from obtained data using BIA evaluation software 3.1 (Biacore AB). In some experiments, the anti-PC antibody TEPC 15 was injected prior to membrane fractions to determine whether the PC-moiety of ES-62 was important for binding.
Preparation of whole cell lysates for Far Western blotting
Cells were pelleted by centrifugation at 400g for 10 min, resuspended in 150 ll lysis buffer pH 7.5 (100 mM Tris base, 300 mM NaCl, 4% (v/v) NP40, 0.5% (v/v) sodium deoxycholate, 2 mM EDTA) containing 1 lg/ml each of chymostatin, leupeptin, antipain and pepstatin A and 1 mM sodium orthovanadate and 10 mM PMSF and solubilized on ice for 20 min. Cellular debris was removed by microfugation at 10,000 rpm for 10 min and the supernatants containing the solubilized whole cell lysates resolved by SDS-PAGE. For Far Western blotting, a biotin conjugate of ES-62 was used in place of the primary antibody and was then detected by an HRPconjugated anti-biotin antibody (diluted 1:2000 in wash buffer containing 5% Marvel). Immunoreactive bands were visualized by the enhanced chemiluminescence (ECL) system (Amersham, Buckinghamshire, UK).
Biotinylation of cell surface proteins and preparation of membrane extracts
Cells (10 8 ) were washed three times and then resuspended in 0.5 ml PBS pH 7.2. Freshly prepared NHS-biotin solution (Pierce) at 4 mg/ml was added and the cells were incubated at room temperature for 30 min on a rocking platform before washing three times in PBS to remove any unbound biotin. The cells were then resuspended in 1.5 ml of ice-cold extraction buffer (50 mM HEPES pH 7.4, 5 mM CaCl 2 , 140 mM NaCl, 1% (v/v) octyl-b-D-glucopyranoside, 1 mM PMSF, 1 mM aprotonin, 1 mM leupeptin) and snap frozen in liquid nitrogen. The sample was then thawed, homogenized in a glass homogeniser (20-30 strokes) and incubated on ice for 1 h. The extract was then centrifuged at 2000 rpm to pellet nuclei and unbroken cells and the resulting supernatant centrifuged at 45,000g for 1 h at 4°C and the supernatant retained as the solubilized membrane extract. For precipitation of ES-62-binding proteins, extracts were precleared by the addition of 50 ll of 50% protein L-agarose washed slurry followed by incubation for 1 h at 4°C on a rotator. Samples were microfuged at 13,000 rpm for 10 min and the pellet discarded. ES-62-FITC (5 lg/ml) was added to the supernatant and incubated for 2 h at 4°C on a rotator. The samples were then incubated with anti-FITC antibodies pre-bound to protein L-agarose (1 lg/50 ll 50% protein L-agarose slurry) overnight at 4°C on a rotator. In some experiments, the biotinylated membranes were preincubated with fucose, PC or an RGDS peptide in an attempt to block binding between ES-62 and polypeptides. The immune complexes were washed three times in PBS pH 7.2, resuspended in SDS-PAGE loading buffer, heated to release the proteins and the beads removed by microfugation prior to resolution of ES-62-binding proteins by SDS-PAGE and detection by an HRP-conjugated anti-biotin antibody.
Preparation of cell extracts for Western blotting analysis of ES-62 binding to, and internalization via, TLR4
Following incubation of the cells with ES-62 (2 lg/ml) at 37°C, the cells were washed three times with ice cold 25 mM Tris-HCl pH 7.4 containing 150 mM NaCl and 100 mM sodium orthovanadate before preparing cell lysates with RIPA buffer as described previously (Feng et al., 1999) and protein concentrations were determined using the microBCA protein assay reagent (Pierce, Rockford, USA). Cell lysates were resolved using the NuPAGE (Invitrogen) and transferred to nitrocellulose according to the manufacturer's instructions. Nitrocellulose filters were then incubated with wash buffer (2 M Tris, pH 7.5 containing 500 mM NaCl and 0.1% (v/ v) Tween-20) containing 5% milk protein for at least 1 h to block non-specific protein binding. The primary antibodies (rabbit anti-ES-62 serum) were diluted 1:100 in wash buffer containing 5% Marvel and applied to the filter for 1 h at room temperature or overnight at 4°C. Following washing, the blots were incubated with HRP-conjugated anti-rabbit IgG (diluted 1:2000 in wash buffer containing 5% Marvel) for 1 h at room temperature (Egan et al., 2006) . Immunoreactive bands were visualized by the enhanced chemiluminescence (ECL) system (Amersham, Buckinghamshire, UK).
Immunofluorescence
Bone marrow-derived macrophages (BMM; 10 3 ) were incubated in 1 ml of Dulbecco's modified eagle medium containing penicillin (100 U/ml), streptomycin (100 lg/ml), 2 mM glutamine and 10% heat-inactivated fetal calf serum (FCS) (DMEM-complete) on 13 mm coverslips in the wells of a 24 well-plate overnight at 37°C in an atmosphere of 5% CO 2 /95% air. The medium was removed and replaced with 1 ml of DMEM-complete containing ES-62 (2 lg/ml) and incubated for a further 3 h. The medium containing ES-62 was removed and the cells fixed in 3% paraformaldehyde/ PBS containing 0.05% Triton X-100 for 20 min at room temperature. Following fixing, the cells were washed (Â2) with PBS containing 1% FCS and then incubated with PBS containing 10% FCS for 15 min at room temperature to prevent subsequent non-specific binding of antibody. The cells were then again washed (Â2) and incubated with KK6-FC4.3, a mouse monoclonal antibody against ES-62 or mouse IgG (10 lg/ml) in PBS containing 1% FCS for 2 h at room temperature. Following washing (Â4), cells were incubated with FITC-labeled goat anti-mouse IgG (dilution as recommended by manufacturer: Sigma, Poole, Dorset, UK) for 90 min at room temperature, washed again (Â4) and coverslips mounted on slides for examination by confocal fluorescence microscopy.
Internalization of [ 35 S]-methionine-labeled ES-62 and analysis of resultant labeled cellular cytosolic fractions
WEHI-231 B cells (10 7 ) per time-point were incubated in a 24 well plate in 1 ml of RPMI 1640 medium supplemented with 5% heat-inactivated fetal calf serum, penicillin (100 U/ml) and streptomycin (100 lg/ml). $15,000 cpm), prepared as described previously was added to each well and the cells incubated at 37°Ci n 5% CO 2 /95% air for the appropriate times. Cells were washed (Â3) with RPMI medium supplemented as before and transferred to centrifuge tubes. Cells were then washed twice with 10 ml ice-cold Tris-buffered saline (TBS) pH 7.6, pelleted by centrifugation at 1500g for 5 min and washed with 1 ml TBS before being transferred to an Eppendorf tube and pelleted again as before. Cytosolic fractions were then prepared according to the nuclear and cytoplasmic extract kit commercially available from active motif and radioactivity of duplicate 10 ll aliquots determined using a liquid scintillation counter.
Results
Biacore analysis of ES-62 interaction with plasma membrane extracts of different cell types
The kinetics of binding of ES-62 to molecules in plasma membrane extracts of monocytes, B cells and T cells was investigated by biacore analysis. This was undertaken by immobilizing ES-62 on the sensor chip and then employing the plasma membranes as analyte. As the kinetics of binding are reflected by the shape of the curve whilst the response units are equivalent to the mass bound, then the observed differences in both parameters likely indicate differences in receptor usage amongst the three cell types. However, as we were using membranes rather than purified proteins, the relative abundance of the individual proteins in the membranes derived from the distinct cell types may confound conclusions regarding the mass of protein bound, indicating that the kinetics are likely to be a better reflection of the differential receptor usage. The curves obtained are indeed suggestive of specific binding consistent with receptor-ligand interactions (Fig. 1) although as mentioned, precise binding kinetics cannot be measured, due to the analyte being impure and a mixture of membrane components. Nevertheless, the variation in the shape of the curve is suggestive of different kinetics of interaction that depends on the source of the membrane, with immobilized ES-62.
Identification of ES-62-binding proteins from different cell types
Several approaches were adopted to determine the nature of ES-62-binding proteins in these different cell types. First, we employed a Far Western blotting procedure using biotinylated ES-62 to identify binding proteins in whole cell extracts. This revealed that in both splenic B cells and Jurkat T cells, ES-62 interacted with proteins of $135 and $82 kDa whereas in U937 monocytes, binding was only observed with a protein of $82 kDa ( Fig. 2A) . Next, we immunoprecipitated ES-62-interacting membrane proteins from surface-biotinylated B cells and U937 cells and employed an anti-biotin-HRP antibody for their detection. As with the Far Western analysis we detected polypeptides of 135 and 82 kDa with respect to B cells but only the 82 kDa molecule in U937 cells (Fig. 2B) . Fig. 1 . ES-62 was immobilised on the biacore sensor chip and the plasma membrane fractions from the indicated different cell origins were passed over the chip surface as analyte. Regeneration was achieved using 100 mM glycine.
The identity of the 82 and 135 kDa proteins has yet to be established. The PAF and mannose receptors can be ruled out as they have predicted molecular weights of 39 and 166 kDa, respectively. The molecular weights of the detected proteins are roughly consistent both with integrin subunits (135 and 82 kDa molecules) and toll-like receptors (82 kDa molecule). Using the surface-biotinylated membrane extracts, we tested for the presence of integrins by determining whether fucose or an RGDS peptide could block interaction between ES-62 and the proteins in WEHI-231 B cell membranes (Kigimoto-Ochiai and Noguchi, 2000) . However, we could find no evidence for the polypeptides being integrins (Fig. 3) . Interestingly however free PC significantly inhibited binding to the two proteins thus demonstrating a likely role for the PC moiety of ES-62 in interactions with them. We also noted by biacore analysis that the anti-PC myeloma protein TEPC 15 prevented interaction between ES-62 and U937 proteins (Fig. 4) . We had previously shown ES-62 activity to be dependent on TLR4 (Goodridge et al., 2005) and hence to determine whether the 82 kDa polypeptide might be TLR4 we undertook Western blotting using an anti-TLR4 antibody. The 82 kDa molecule in U937 cells and Jurkat T cells was not recognized by the antibody whereas the 82 kDa molecule in splenic B cells was weakly recognized by the antibody but in addition, by an anti-TLR2 antibody (results not shown). The results with the U937 and Jurkat T cells are perhaps not surprising as only 2% of the former express TLR4 (Romano Caratelli et al., 2010) and TLR4 is absent from the latter (Ye and Gan, 2007) . The result with the B cells (which are known to express TLR4) may simply reflect cross-reactivity between antibodies but if this is the case and the molecule being detected is truly TLR4, then it would appear to be distinct from the 82 kDa molecule being detected in the other cells.
TLR4 is essential for internalization of ES-62 in macrophages but not B cells
Previously we have shown that ES-62 is internalized by mast cells (Melendez et al., 2007 ) and we now demonstrate by the use of immunofluorescence that the same is true of macrophages ( Fig. 5A and B) . Furthermore, incubation of B cells with [
35 S]-methionine radiolabeled ES-62 and subsequent cell fractionation resulted in the molecule being clearly detected in a cytoplasmic extract within 1 h (Fig. 5C) cells of the immune system tend to internalize ES-62. Our previous studies have also revealed via the use of knockout mice that for ES-62 to inhibit pro-inflammatory cytokine production by macrophages, the cells must express both TLR4 and MyD88 (Goodridge et al., 2005) . TLR4 is present at the macrophage surface and hence similar to the situation with LPS, it may act as a receptor for ES-62. Consistent with this, ES-62 is bound and internalized by wild type and MyD88 À/À macrophages but not TLR4 À/À macrophages ( Fig. 5D  and E) . However, ES-62 is internalized by each of wild type, MyD88
À/À and TLR4 À/À splenic B cells ( Fig. 5F and G) . Thus, clearly the two cell types are using different receptors or combinations of receptors for ES-62 binding and internalization.
Discussion
ES-62 has been subject to study since 1989 and its immunomodulatory properties first documented in 1993 (reviewed by Harnett and Harnett (2009) ). The first immunomodulatory study focused on the B cell and since then ES-62 has been studied with respect to T cells and T cell lines, B1 cells, macrophages, dendritic cells and mast cells (reviewed by Harnett and Harnett (2009) ). The only cell population investigated that was found to be unaffected by exposure to ES-62 was human tonsil T cells (Harnett et al., 1998) and this could perhaps be explained by these cells failing to express the ''ES-62 receptor''. Subsequent work in APC that made use of knockout mice indicated that TLR4 expression was essential for the immunomodulatory action of ES-62 (Goodridge et al., 2005 (Goodridge et al., , 2007 and this was supported by knockdown studies in mast cells (Melendez et al., 2007) . These studies therefore suggested that TLR4 was the receptor for ES-62. However they did not rule out the existence of co-receptors or other receptors for the helminth product and indeed there is evidence to suggest that ES-62 can bind to both the mannose receptor and the PAF receptor even although the biological significance of such interactions has yet to be established ( (Goodridge et al., 2007) and unpublished results). Furthermore, it was unknown as to whether the critical role that TLR4 plays in facilitating ES-62 in APC and mast cells also applied to other cell types. Indeed Jurkat T cells are receptive to the 
